Vasopressors in Septic Shock - Selection and Titration

Key Points

• Norepinephrine is first-line vasopressor therapy for adult septic shock.
• Do not delay norepinephrine in profound hypotension solely to finish a predetermined fluid volume.
• A usual initial MAP target is about 65 mm Hg, then individualized to perfusion and comorbidity.
• Add vasopressin when norepinephrine needs escalate; add epinephrine if pressure remains inadequate despite both.
• Peripheral norepinephrine is acceptable for prompt initiation through a suitable monitored vein.
• Repeatedly reassess volume responsiveness and cardiac function before giving more fluid or escalating catecholamines.
• Pressure normalization without improved capillary refill, mentation, urine output, or lactate trajectory may represent incomplete resuscitation.

Algorithm

1. Treat infection and begin source-control planning while initiating hemodynamic resuscitation.
2. Give balanced crystalloid when fluid responsive or clinically volume depleted; reassess after each bolus.
3. Start norepinephrine promptly for persistent or severe hypotension and target an initial MAP near 65 mm Hg.
4. Use capillary refill, urine output, lactate trend, mental status, and dynamic hemodynamic assessment to judge response.
5. Add vasopressin for escalating norepinephrine requirement rather than relying on unlimited catecholamine dose escalation.
6. Add epinephrine if MAP remains inadequate despite norepinephrine and vasopressin.
7. If hypoperfusion persists despite adequate pressure, evaluate septic cardiomyopathy and consider inotropic support.
8. De-resuscitate after shock stabilization when fluid overload is present and ongoing fluid is no longer beneficial.

Clinical Synopsis & Reasoning

Septic shock is vasodilatory shock with variable hypovolemia and myocardial dysfunction. The hemodynamic problem therefore changes over time: an early patient may need both crystalloid and vasopressor support, while a later patient may be fluid replete, profoundly vasoplegic, or developing septic cardiomyopathy. Vasopressor selection must be linked to repeated bedside assessment rather than to a fixed sequence divorced from physiology.

The 2026 Surviving Sepsis Campaign continues to recommend norepinephrine as the first-line agent. Norepinephrine provides potent alpha-adrenergic vasoconstriction with modest beta activity and generally produces fewer tachyarrhythmias than dopamine. A usual initial mean arterial pressure target is approximately 65 mm Hg, then individualized for chronic hypertension, cerebral or coronary perfusion concerns, arrhythmia risk, and evidence of tissue perfusion. Pressure is only a surrogate. Urine output, capillary refill, mental status, skin perfusion, lactate trajectory, and organ function determine whether circulation is actually improving.

Persistent hypotension does not automatically mean the norepinephrine dose should continue rising. Reassess for occult hypovolemia, hemorrhage, tension pneumothorax, tamponade, pulmonary embolism, adrenal insufficiency, myocardial dysfunction, excessive sedation, or uncontrolled source. Bedside echocardiography and dynamic fluid-responsiveness tests can help distinguish additional volume need from vasoplegia or low cardiac output.

Treatment Strategy & Disposition

Start norepinephrine promptly when hypotension persists during initial resuscitation or when profound hypotension makes waiting for completion of a fluid bolus unsafe. A well-sited peripheral IV can be used to avoid harmful delays while central access is arranged when prolonged or high-dose therapy is expected. Monitor the site frequently and follow local extravasation protocols.

Titrate norepinephrine to the lowest dose that achieves an adequate pressure and perfusion target. When norepinephrine requirements are escalating, add vasopressin rather than simply continuing catecholamine escalation in many patients. Vasopressin is commonly used as a fixed-dose adjunct rather than titrated as the primary vasopressor. If MAP remains inadequate despite norepinephrine and vasopressin, add epinephrine. In septic shock with significant cardiac dysfunction and persistent hypoperfusion despite adequate pressure and volume status, inotropic support such as dobutamine or an epinephrine-based strategy may be considered according to the hemodynamic profile.

Obtain source control and effective antimicrobials in parallel because vasopressors do not treat the cause of shock. After the acute resuscitation phase, actively avoid unnecessary positive fluid balance and consider fluid removal when appropriate. Corticosteroids can be used in vasopressor-dependent septic shock according to current sepsis guidance and local protocol. Reassess every escalation for ischemic complications, arrhythmia, lactate trend, urine output, capillary refill, and whether the target MAP remains appropriate.

Epidemiology / Risk Factors

• Septic shock remains a common cause of vasodilatory shock in adult ICUs.
• Older age, immunosuppression, delayed source control, and multi-organ failure are associated with higher mortality.
• Myocardial dysfunction is common enough in septic shock that persistent hypoperfusion should not be assumed to be pure vasoplegia.
• Excess positive fluid balance after the resuscitation phase is associated with complications and should prompt active reassessment.

Investigations

Common Vasopressors

Pharmacology

Prognosis / Complications

• Rapid restoration of adequate perfusion and early source control are major determinants of outcome.
• Persistent hyperlactatemia, oliguria, mottling, or delayed capillary refill despite adequate MAP signals higher risk.
• Rising vasopressor requirements usually indicate worsening shock severity or an uncorrected physiologic problem.
• Survivors of prolonged septic shock often require rehabilitation for weakness, cognitive symptoms, and organ recovery.

Patient Education / Counseling

• Explain that vasopressors support blood pressure while antibiotics, drainage, surgery, or other source control treat the infection itself.
• Families should understand that medication doses can rise or fall rapidly as circulation changes.
• Discuss arterial and central-line placement as monitoring and delivery tools rather than treatments for sepsis.
• When shock remains severe, communicate prognosis using the full pattern of organ failure rather than vasopressor dose alone.

Notes

Vasopressor escalation should be viewed as a diagnostic checkpoint. If the dose is rising quickly, ask whether the patient still needs fluid, has lost blood, has obstructive shock, has severe myocardial dysfunction, or lacks source control. A medication ladder without this reassessment can produce acceptable numbers while tissue perfusion continues to fail.

The 2026 sepsis guideline strengthens the central role of norepinephrine and supports capillary refill as an adjunctive resuscitation endpoint. It also emphasizes active fluid removal after the acute phase in appropriate patients, reinforcing that shock treatment has a resuscitation phase and a de-resuscitation phase.

References

1. Surviving Sepsis Campaign International Guidelines for Management of Sepsis and Septic Shock 2026 — Link
2. Society of Critical Care Medicine Guidelines Library — Link